Terms: = Leukemia AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
45 results:
1. Molecular modeling study of pyrrolidine derivatives as novel myeloid cell leukemia-1 inhibitors through combined 3D-QSAR, molecular docking, ADME/Tox and MD simulation techniques.
Tabti K; Baammi S; Sbai A; Maghat H; Lakhlifi T; Bouachrine M
J Biomol Struct Dyn; 2023; 41(23):13798-13814. PubMed ID: 36841617
[TBL] [Abstract] [Full Text] [Related]
2. Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study.
Aceves-Hernández JM; Inés Nicolás Vázquez M; Luis Garza Rivera J; Espinoza Godínez A; Mateo Flores J; de Jesús Cruz Guzmán J; Castaño VM
Chem Biodivers; 2023 Mar; 20(3):e202200554. PubMed ID: 36799136
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Jacobs SS; Dome JS; Gai J; Gross AM; Postell E; Hinds PS; Davenport L; van den Anker JN; Mowbray C
Support Care Cancer; 2022 Apr; 30(4):3513-3520. PubMed ID: 35018520
[TBL] [Abstract] [Full Text] [Related]
4. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptional Profiling and Biological Pathway(s) Analysis of Type 2 Diabetes Mellitus in a Pakistani Population.
Noreen Z; Loffredo CA; Bhatti A; Simhadri JJ; Nunlee-Bland G; Nnanabu T; John P; Khan JS; Ghosh S
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823525
[TBL] [Abstract] [Full Text] [Related]
6. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract] [Full Text] [Related]
7. CYP1A1 and cyp2d6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia.
Idris HME; Khalil HB; Mills J; Elderdery AY
Curr Cancer Drug Targets; 2020; 20(9):675-680. PubMed ID: 32418524
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.
Tian X; Zhang H; Heimbach T; He H; Buchbinder A; Aghoghovbia M; Hourcade-Potelleret F
J Clin Pharmacol; 2018 Dec; 58(12):1533-1540. PubMed ID: 30179260
[TBL] [Abstract] [Full Text] [Related]
9. Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and cyp2d6*4 Polymorphism in the Etiology of Childhood Acute leukemia.
Ferri GM; Guastadisegno CM; Intranuovo G; Cavone D; Birtolo F; Cecinati V; Pappalardi B; Corsi P; Vimercati L; Santoro N
J Pediatr Hematol Oncol; 2018 May; 40(4):e207-e214. PubMed ID: 29432309
[TBL] [Abstract] [Full Text] [Related]
10. Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.
Kim IW; Han N; Kim MG; Kim T; Oh JM
Pharmacogenet Genomics; 2015 Jan; 25(1):1-7. PubMed ID: 25379720
[TBL] [Abstract] [Full Text] [Related]
11. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
He H; Yin JY; Xu YJ; Li X; Zhang Y; Liu ZG; Zhou F; Zhai M; Li Y; Li XP; Wang Y; Zhou HH; Liu ZQ
Clin Ther; 2014 Aug; 36(8):1242-1252.e2. PubMed ID: 25012726
[TBL] [Abstract] [Full Text] [Related]
12. No association between cytochrome P450 2D6 gene polymorphism and risk of acute leukemia: evidence based on a meta-analysis.
Ruan XL; Li S; Zeng XT; Xia LH; Hu Y
Chin Med J (Engl); 2013; 126(19):3750-3. PubMed ID: 24112176
[TBL] [Abstract] [Full Text] [Related]
13. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
[TBL] [Abstract] [Full Text] [Related]
14. [Relationships between the gene polymorphisms of drug metabolizing enzymes and the outcome of the first induction chemotherapy in patients with de novo acute myeloid leukemia].
Wang N; Han JL; Mi YC; Xiao ZJ; Feng SZ; Zhou YL; Wang JX; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):327-31. PubMed ID: 21518482
[TBL] [Abstract] [Full Text] [Related]
15. Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.
Łapiński Ł; Orzechowska-Juzwenko K; Wiela-Hojeńska A; Wołowiec D; Ganczarski G; Głowacka K; Czarnik-Matusewicz H; Kuliczkowski K; Gąsiorowski J
Pharmacol Rep; 2011; 63(1):149-56. PubMed ID: 21441622
[TBL] [Abstract] [Full Text] [Related]
16. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract] [Full Text] [Related]
17. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, cyp2d6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians.
Gra O; Mityaeva O; Berdichevets I; Kozhekbaeva Z; Fesenko D; Kurbatova O; Goldenkova-Pavlova I; Nasedkina T
Genet Test Mol Biomarkers; 2010 Jun; 14(3):329-42. PubMed ID: 20373852
[TBL] [Abstract] [Full Text] [Related]
18. Role of the cyp2d6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.
Silveira Vda S; Canalle R; Scrideli CA; Queiroz RG; Tone LG
Environ Mol Mutagen; 2010 Jan; 51(1):48-56. PubMed ID: 19593802
[TBL] [Abstract] [Full Text] [Related]
19. Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.
da Silva Silveira V; Canalle R; Scrideli CA; Queiroz RG; Bettiol H; Valera ET; Tone LG
Leuk Res; 2009 Jul; 33(7):898-901. PubMed ID: 19162321
[TBL] [Abstract] [Full Text] [Related]
20. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract] [Full Text] [Related]
[Next]
